CEO Kadia highlights execution fixes and debt reduction amid SDC fulfillment challenges.

Moby summary of Mesa Laboratories, Inc.'s Q1 2027 earnings call

Adjusted operating income surges nearly 20% as the company returns to core organic growth and strengthens its balance sheet.

Mesa Laboratories (NASDAQ:MLAB) reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control busine

Over the last 7 days, the United States market has risen by 4.0%, contributing to a remarkable 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this dynamic environment, identifying good stocks often involves looking for companies that are not only undervalued but also show signs of insider confidence, such as recent buying activity.

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. As many believe, US equities experienced solid returns in 2025, with double-digit gains across all major indices, yet underlying conditions revealed extreme volatility and market leadership. A copy of the letter can be downloaded here. In Q4 2025, Conestoga Capital Advisors Small Cap Strategy […]

Most readers would already be aware that Mesa Laboratories' (NASDAQ:MLAB) stock increased significantly by 22% over the...